Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celebrido: Neoadjuvant celecoxib in endometrial carcinoma
2019-001071-37Phase 2Completed
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of celecoxib in endometrioid adenocarcinoma, sponsored by Cliniques universitaires Saint-Luc. Primary endpoint: Tumoral IDO1 reduction and CD3+ T-cell infiltration increase. Started May 2019; status: completed.
02
Drugs
celecoxib
03
Conditions
endometrioid adenocarcinoma
Beyond the preview
Go deeper on 2019-001071-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001071-37.